PMID- 32847422
OWN - NLM
STAT- MEDLINE
DCOM- 20210907
LR  - 20210907
IS  - 1097-9883 (Electronic)
IS  - 0360-2532 (Linking)
VI  - 52
IP  - 4
DP  - 2020 Nov
TI  - HLA transgenic mice: application in reproducing idiosyncratic drug toxicity.
PG  - 540-567
LID - 10.1080/03602532.2020.1800725 [doi]
AB  - Various types of transgenic mice carrying either class I or II human leukocyte 
      antigen (HLA) molecules are readily available, and reports describing their use 
      in a variety of studies have been published for more than 30 years. Examples of 
      their use include the discovery of HLA-specific antigens against viral infection 
      as well as the reproduction of HLA-mediated autoimmune diseases for the 
      development of therapeutic strategies. Recently, HLA transgenic mice have been 
      used to reproduce HLA-mediated idiosyncratic drug toxicity (IDT), a rare and 
      unpredictable adverse drug reaction that can result in death. For example, 
      abacavir-induced IDT has successfully been reproduced in HLA-B*57:01 transgenic 
      mice. Several reports using HLA transgenic mice for IDT have proven the utility 
      of this concept for the evaluation of IDT using various HLA allele combinations 
      and drugs. It has become apparent that such models may be a valuable tool to 
      investigate the mechanisms underlying HLA-mediated IDT. This review summarizes 
      the latest findings in the area of HLA transgenic mouse models and discusses the 
      current challenges that must be overcome to maximize the potential of this unique 
      animal model.
FAU - Susukida, Takeshi
AU  - Susukida T
AD  - Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba 
      University, Chiba, Japan.
AD  - Laboratory of Cancer Biology and Immunology, Section of Host Defenses, Institute 
      of Natural Medicine, University of Toyama, Toyama, Japan.
FAU - Aoki, Shigeki
AU  - Aoki S
AD  - Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba 
      University, Chiba, Japan.
FAU - Shirayanagi, Tomohiro
AU  - Shirayanagi T
AD  - Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba 
      University, Chiba, Japan.
FAU - Yamada, Yushiro
AU  - Yamada Y
AD  - Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba 
      University, Chiba, Japan.
FAU - Kuwahara, Saki
AU  - Kuwahara S
AD  - Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba 
      University, Chiba, Japan.
FAU - Ito, Kousei
AU  - Ito K
AUID- ORCID: 0000-0001-7187-9639
AD  - Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba 
      University, Chiba, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200827
PL  - England
TA  - Drug Metab Rev
JT  - Drug metabolism reviews
JID - 0322067
RN  - 0 (Antiviral Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (HLA Antigens)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Alleles
MH  - Animals
MH  - Antiviral Agents/therapeutic use/*toxicity
MH  - Dideoxynucleosides/therapeutic use/toxicity
MH  - *Disease Models, Animal
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - HLA Antigens/*genetics
MH  - Humans
MH  - Mice
MH  - *Mice, Transgenic
MH  - Virus Diseases/*drug therapy
OTO - NOTNLM
OT  - HLA
OT  - animal model
OT  - idiosyncratic drug toxicity
OT  - immunotoxicity
OT  - transgenic mice
EDAT- 2020/08/28 06:00
MHDA- 2021/09/08 06:00
CRDT- 2020/08/28 06:00
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2021/09/08 06:00 [medline]
PHST- 2020/08/28 06:00 [entrez]
AID - 10.1080/03602532.2020.1800725 [doi]
PST - ppublish
SO  - Drug Metab Rev. 2020 Nov;52(4):540-567. doi: 10.1080/03602532.2020.1800725. Epub 
      2020 Aug 27.